Compare BioNTech SE - ADR (BNTX) vs Cintas Corporation (CTAS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs Cintas Corporation — how do they compare? BioNTech SE - ADR trades at $93.44 (market cap $23.31B), while Cintas Corporation trades at $204.11 (market cap $82.15B). The key difference: Cintas Corporation is far larger — about 3.5× BioNTech SE - ADR's market cap, and Cintas Corporation pays a 1.01% dividend while BioNTech SE - ADR pays none. Which is the better fit depends on your goals.
| BNTX | CTAS | |
|---|---|---|
Market Cap | $23.31B | $82.15B |
Sector | Health | Industrials |
52-Week High | $119.34 | $225.10 |
52-Week Low | $83.89 | $163.55 |
Enterprise Value | $6.60B | $84.56B |
Dividend Yield | — | 1.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $93.27, up 0.51% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported Q2 2026 revenue of $106 million, missing expectations, and lowered its full-year sales outlook due to weak COVID-19 vaccine demand. Despite negative net income margins and cash outflows, BNTX maintains a strong cash position of $16.78 billion and is advancing its oncology pipeline with 14 pivotal clinical trials.
The outlook is mixed: analyst consensus is strongly bullish with a $121 price target, but declining COVID revenue and ongoing losses pose significant risks. Investment opportunity hinges on successful pipeline development, while near-term headwinds from vaccine demand softness and leadership transition require careful monitoring.
Cintas (CTAS) trades at $204.86, up 1.06% on the day, with a bullish technical signal and recent earnings beats driving positive momentum. The company reported strong Q2 2026 EPS of $1.29, exceeding expectations, and maintains robust fundamentals with a 17.75% net income margin and 40.59% ROE. Revenue growth is steady, reaching $10.34B in 2025, supported by consistent profitability and a dividend payout.
The outlook is positive, with a consensus price target of $225.83 implying ~10% upside, though high valuation ratios (P/E 41.81) and competitive pressures pose risks. Institutional interest is strong, with recent upgrades, but investors should monitor debt levels and economic sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About Cintas Corporation
In its core uniform and facility services unit (78% of sales), Cintas provides uniform rental programs to businesses across the size spectrum, mostly in North America. The firm is by far the largest provider in the industry. Facilities products generally include the rental and sale of entrance mat, mops, shop towels, hand sanitizers, and restroom supplies. Cintas also runs a first aid and safety services business (11% of sales), a fire protection services business (7% of sales), and a uniform direct sales business (4% of sales).
Read more on CTAS →
